Bisphosphonate induces apoptosis and inhibits pro‐osteoclastic gene expression in prostate cancer cells
Open Access
- 1 May 2006
- journal article
- Published by Wiley in International Journal of Urology
- Vol. 13 (5), 593-600
- https://doi.org/10.1111/j.1442-2042.2006.01360.x
Abstract
Aim: Bisphosphonates are well established for the management of cancer-induced skeletal complications. Recent studies suggest that bisphosphonates promote apoptosis of cancer cells as well as osteoclasts in bone metastatic sites. To determine the direct effects of bisphosphonate on prostate cancer, we examined the effects of minodronate on prostatic cancer cell growth and the expression of apoptosis-related proteins and osteoclastogenic factors. Methods: PC-3, DU145 and LNCaP cells were treated with amino-bisphosphonate minodronate. Then proliferation, apoptosis and expression of bcl-2, bax, poly (ADP)-ribose polymerase (PARP), caspase-3, receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinases-2 (MMP-2), and parathyroid hormone related protein (PTHrP) were assessed. Results: The proliferation of prostatic cancer cells was inhibited by minodronate. DNA fragmentation and TUNEL-positive nuclei were observed in minodronate-treated PC-3 cells. Minodronate decreased bcl-2 expression and induced bax expression, caspase-3 activity and degradation of PARP in DU145 and PC-3 cells. Minodronate decreased expression of RANKL, PTHrP and MMP-2 in PC-3 cells. Conclusions: Our results suggest that bisphosphonate not only promotes apoptosis directly but also decreases pro-osteoclastic gene expression in prostate cancer cellsKeywords
This publication has 45 references indexed in Scilit:
- The Bisphosphonate YM529 Inhibits Osteolytic and Osteoblastic Changes and CXCR-4–Induced Invasion in Prostate CancerCancer Research, 2005
- Nitrogen Containing Bisphosphonates Induce Apoptosis and Inhibit the Mevalonate Pathway, Impairing Ras Membrane Localization in Prostate Cancer CellsJournal of Urology, 2003
- Bisphosphonate Therapy for Hormone Refractory Prostate Cancer with Bone MetastasisJournal of Urology, 2003
- Bisphosphonates Pamidronate and Zoledronic Acid Stimulate Osteoprotegerin Production by Primary Human OsteoblastsBiochemical and Biophysical Research Communications, 2002
- THE USE OF BISPHOSPHONATE FOR THE PALLIATIVE TREATMENT OF PAINFUL BONE METASTASIS DUE TO HORMONE REFRACTORY PROSTATE CANCERJournal of Urology, 2001
- INCIDENCE OF SKELETAL COMPLICATIONS IN PATIENTS WITH BONE METASTATIC PROSTATE CANCER AND HORMONE REFRACTORY DISEASE: PREDICTIVE ROLE OF BONE RESORPTION AND FORMATION MARKERS EVALUATED AT BASELINEJournal of Urology, 2000
- Osteotropic Agents Regulate the Expression of Osteoclast Differentiation Factor and Osteoprotegerin in Osteoblastic Stromal CellsEndocrinology, 1998
- EXPRESSION OF MATRIX METALLOPROTEINASE-7 AND TISSUE INHIBITOR OF METALLOPROTEINASE-1 IN HUMAN PROSTATEJournal of Urology, 1998
- Bcl-2 and the regulation of programmed cell deathThe Journal of cell biology, 1994
- Skeletal MetastasesClinical Orthopaedics and Related Research, 1986